BioTuesdays

HCW transfers coverage of uniQure at buy

Mark Breidenback of H.C. Wainwright has assumed coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $30 price target. The stock closed at $14.89 on Tuesday.uniQure is developing gene therapies as long-acting...

WB starts Collegium Pharma at outperform

William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday.Collegium’s lead product, Xtampza ER...

Novadaq posts 54% jump in Q4 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015.Product sales...

Titan Medical offering raises $10.5-million

Titan Medical (OTCQX:TITXF; TSX:TMD) has closed a public offering of 11,670,818 units at a price of 90 cents each for gross proceeds of $10.5-million.Each unit consists of one common share and one warrant, with each...

Bionomics

Roth starts Bionomics at buy

Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday.“We believe a significant disconnect exists on the...

Leerink downgrades Carbylan to market perform

Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for...

Rodman starts EyeGate Pharma at buy

Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday."In our view, the company’s EGP-437...

Rodman starts VolitionRx at buy

Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday.“In our view, the company’s blood-based NuQ screening...

Rodman starts BioBlast Pharma at buy

Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday.BioBlast is focused on platform-based solutions...

HCW starts Seres Therapeutics at buy

H.C. Wainwright has initiated coverage of Seres Therapeutics (NASDAQ:MCRB) with a “buy” rating and $55 price target. The stock closed at $24.88 on Friday.Seres is developing restorative microbial treatments that aim to...

Subscribe

Sign up to our weekly BioTuesdays newsletter.